TITLE

Peginterferon &Alfa;-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections

AUTHOR(S)
Chung, R.T.
PUB. DATE
January 2005
SOURCE
ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p10
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that peginterferon &Alfa;-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections. More patients in the peginterferon α2a plus ribavirin group than in the interferon α-2a plus ribavirin group had a virologie response throughout follow-up. In patients with both HIV and hepatitis C virus infections, peginterferon α-2a plus ribavirin was more effective than interferon α-2a plus ribavirin for inducing a hepatitis C virologie response.
ACCESSION #
15851775

 

Related Articles

  • Addition of Nitazoxanide to PEG-IFN and Ribavirin to Improve HCV Treatment Response in HIV-1 and HCV Genotype 1 Coinfected Persons Naïve to HCV Therapy: Results of the ACTG A5269 Trial. Amorosa, Valerianna K.; Luetkemeyer, Anne; Kang, Minhee; Johnson, Victoria A.; Umbleja, Triin; Haas, David W.; Yesmin, Suria; Bardin, Matthew C.; Chung, Ray T.; Alston-Smith, Beverly; Tebas, Pablo; Peters, Marion G. // HIV Clinical Trials;Nov/Dec2013, Vol. 14 Issue 6, p274 

    Background: We hypothesized that nitazoxanide (NTZ) added to pegylated interferon alfa-2a (PEG-IFN) and weight-based ribavirin (WBR) would improve hepatitis C virus (HCV) virologic responses in HCV treatment-naïve HIV-1/HCV genotype 1 coinfected persons. Methods: Prospective, single-arm study...

  • Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin. Sede, M.; Laufer, N.; Ojeda, D.; Gun, A.; Cahn, P.; Quarleri, J. // Archives of Virology;Sep2013, Vol. 158 Issue 9, p1907 

    Even though new drugs have been approved for treatment of hepatitis C virus (HCV) infection, the risk of drug-drug interactions and concern about overlapping toxicities has hindered the development of studies in HIV/HCV-coinfected individuals. Traditional treatment with pegylated interferon plus...

  • HIV: The mixed blessing of interferon. Telenti, Amalio // Nature;7/31/2014, Vol. 511 Issue 7511, p537 

    The article focuses on the role of interferon-stimulated proteins in the treatment for HIV-infected patients by referring to a study by N.G. Sandler and colleagues which reported the benefit of the interferon IFNα2a in preventing systemic viral infection. Topics discussed include discussion...

  • Challenges in the Management of HIV and Hepatitis C Virus Co-infection. Lee, Winston; Dieterich, Douglas // Drugs;2004, Vol. 64 Issue 7, p693 

    Hepatitis C virus (HCV) has become a significant contributor to morbidity and mortality to those infected with HIV since the introduction of highly active antiretroviral therapy (HAART). The presence of HIV clearly has a negative effect on the natural history of HCV, although there is some...

  • A 24-Week Treatment Strategy With Pegylated Interferon/Ribavirin in HIV/Hepatitis C Virus Genotype 3–Coinfected Patients Who Achieved a Rapid Virologic Response Results in a High Sustained Virologic Response Rate. Rivero-Juarez, Antonio; López-Cortés, Luis F.; Camacho, Angela; Mira, Jose A.; Téllez, Francisco; Marquez, Manuel; Merino, Dolores; Pineda, Juan A.; Rivero, Antonio // Clinical Infectious Diseases;Jan2014, Vol. 58 Issue 1, p130 

    We designed a study to evaluate the efficacy of a 24-week treatment strategy in HIV/hepatitis C virus (HCV) genotype 3–coinfected patients achieving rapid virologic response for a first HCV treatment with pegylated interferon plus ribavirin (peg-IFN/RBV). Our results suggest that a...

  • Benefits From Sustained Virologic Response to Pegylated Interferon Plus Ribavirin in HIV/Hepatitis C Virus–Coinfected Patients With Compensated Cirrhosis. Mira, José A.; Rivero-Juárez, Antonio; López-Cortés, Luis F.; Girón-González, José A.; Téllez, Francisco; Santos-Gil, Ignacio de los; Macías, Juan; Merino, Dolores; Márquez, Manuel; Ríos-Villegas, María J.; Gea, Isabel; Merchante, Nicolás; Rivero, Antonio; Torres-Cornejo, Almudena; Pineda, Juan A. // Clinical Infectious Diseases;Jun2013, Vol. 56 Issue 11, p1646 

    The achievement of sustained virologic response following pegylated interferon plus ribavirin treatment is associated with a marked reduction of the risk of hepatic decompensations and overall mortality in HIVinfected patients with compensated hepatitis C virus–related...

  • Hepatitis C. Alper, Brian S.; Selius, Brian A. // Cortlandt Forum;7/25/2005, Vol. 18 Issue 7, p59 

    Presents an overview of hepatitis C. Number of people infected by hepatitis C; Etiology of hepatitis C virus; Prognosis of patient with hepatitis C virus infection.

  • Predictive Factors for Sustained Virological Response after Treatment with Pegylated Interferon α-2a and Ribavirin in Patients Infected with HCV Genotypes 2 and 3. Niederau, Claus; Mauss, Stefan; Schober, Andreas; Stoehr, Albrecht; Zimmermann, Tim; Waizmann, Michael; Moog, Gero; Pape, Stefan; Weber, Bernd; Isernhagen, Konrad; Sandow, Petra; Bokemeyer, Bernd; Alshuth, Ulrich; Steffens, Hermann; Hüppe, Dietrich // PLoS ONE;Sep2014, Vol. 9 Issue 9, p1 

    Background: Previous trials have often defined genotype 2 and 3 patients as an “easy to treat” group and guidelines recommend similar management. Aims: The present study looks for differences between the two genotypes and analyzes predictive factors for SVR. Methods: Prospective,...

  • Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. McHutchison, John G.; Lawitz, Eric J.; Shiffman, Mitchell L.; Muir, Andrew J.; Galler, Greg W.; McCone, Jonathan; Nyberg, Lisa M.; Lee, William M.; Ghalib, Reem H.; Schiff, Eugene R.; Galati, Joseph S.; Bacon, Bruce R.; Davis, Mitchell N.; Mukhopadhyay, Pabak; Koury, Kenneth; Noviello, Stephanie; Pedicone, Lisa D.; Brass, Clifford A.; Albrecht, Janice K.; Sulkowski, Mark S. // New England Journal of Medicine;8/6/2009, Vol. 361 Issue 6, p580 

    Background: Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared. Methods: At 118 sites, patients who had HCV genotype 1...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics